BioCentury
ARTICLE | Company News

Biogen returns gene therapies to AGTC on lack of clinical activity

December 14, 2018 7:32 PM UTC

Applied Genetic Technologies Corp. (NASDAQ:AGTC) said late Dec. 12 that Biogen Inc. (NASDAQ:BIIB) terminated the companies’ gene therapy collaboration, leaving behind a partnership originally established to help Biogen build its gene therapy expertise. AGTC was down $3.09 (47%) to $3.47 on Dec. 13.

Biogen made the decision to end the partnership after AGTC reported interim six-month data from a Phase I/II trial that showed gene therapy rAAV2tYF-CB-hRS1 did not lead to any signs of clinical activity among 27 patients with X-linked retinoschisis (XLRS). rAAV2tYF-CB-hRS1 is a recombinant adeno-associated virus (AAV) vector delivering retinoschisis X-linked juvenile 1 (RS1; XLRS1)...